# accelerated approval (blogs) — RSS Amplifier Recent posts from the 1 feeds in the RSS Amplifier directory that cover accelerated approval. Page: Feed: --- ## [WellSpan and Johns Hopkins renew partnership for advanced cancer care access](https://pharmaceutical-business-review.com/news/wellspan-johns-hopkins-advanced-cancer-care/) _2026-08-21 · Salong Debbarma · Pharmaceutical Business review_ The development marks the next stage of a partnership that began in 2017 and saw further expansion in 2021. Over the last five years, more than 1,300 WellSpan The post WellSpan and Johns Hopkins renew partnership for advanced cancer care access appeared first on Pharmaceutical Business review . ## [Charles River and MVC to develop enterovirus vaccine](https://pharmaceutical-business-review.com/news/charles-river-mvc-enterovirus-vaccine/) _2026-08-21 · Salong Debbarma · Pharmaceutical Business review_ Utilising its analytical platforms such as next-generation sequencing (NGS), Charles River will assist with chemistry, manufacturing, and controls (CMC) activities related to the vaccine’s development. The agreement aims The post Charles River and MVC to develop enterovirus vaccine appeared first on Pharmaceutical Business review . ## [FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy](https://pharmaceutical-business-review.com/news/fda-approval-ultragenyx-genglycos-gene-therapy/) _2026-08-20 · Salong Debbarma · Pharmaceutical Business review_ The approval covers both adult and paediatric patients aged eight years and above. GSDIa is a rare genetic metabolic disorder caused by a deficiency in the enzyme required The post FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy appeared first on Pharmaceutical Business review . ## [SandboxAQ introduces AQPotency for virtual drug screening](https://pharmaceutical-business-review.com/news/sandboxaq-aqpotency-virtual-drug-screening/) _2026-08-20 · Salong Debbarma · Pharmaceutical Business review_ AQPotency is accessible through Claude via the Model Context Protocol (MCP), as well as through the SandboxAQ website, with plans for listing on Google Cloud’s Marketplace. It enables The post SandboxAQ introduces AQPotency for virtual drug screening appeared first on Pharmaceutical Business review . ## [Andelyn Biosciences to develop GM2 gangliosidosis therapy](https://pharmaceutical-business-review.com/news/andelyn-to-develop-gm2-gangliosidosis-therapy/) _2026-08-19 · Salong Debbarma · Pharmaceutical Business review_ The partnership aims to progress this gene therapy using Andelyn’s AAV Curator Platform. GM2 gangliosidosis is a rare genetic disorder that leads to the progressive loss of nerve The post Andelyn Biosciences to develop GM2 gangliosidosis therapy appeared first on Pharmaceutical Business review . ## [BeOne Medicines and partners renew Brukinsa access programme for CLL](https://pharmaceutical-business-review.com/news/beone-medicines-partners-renew-brukinsa-programme/) _2026-08-19 · Salong Debbarma · Pharmaceutical Business review_ The renewed agreement is expected to reach approximately 1,000 patients cumulatively by its conclusion. This partnership, which began in 2023, has so far provided Brukinsa to more than The post BeOne Medicines and partners renew Brukinsa access programme for CLL appeared first on Pharmaceutical Business review . ## [Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status](https://pharmaceutical-business-review.com/news/faeths-combo-fda-fast-track-status/) _2026-08-18 · Salong Debbarma · Pharmaceutical Business review_ The designation applies specifically to patients whose tumours contain a phosphatidylinositol 3-kinase / protein kinase B / mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway alteration. It also applies to The post Faeth’s PIKTOR plus paclitaxel combo gains FDA fast track status appeared first on Pharmaceutical Business review . ## [Fulcrum and Slate Medicines sign merger agreement](https://pharmaceutical-business-review.com/news/fulcrum-slate-medicines-merger-agreement/) _2026-08-18 · Salong Debbarma · Pharmaceutical Business review_ The combined organisation, which will operate as Slate Medicines, is expected to be listed on Nasdaq under the “SLTE” ticker symbol. Following completion of the merger, the new The post Fulcrum and Slate Medicines sign merger agreement appeared first on Pharmaceutical Business review . ## [EMA validates Pfizer and Valneva’s Lyme disease vaccine](https://pharmaceutical-business-review.com/news/ema-pfizer-valnevas-lyme-disease-vaccine/) _2026-08-17 · Salong Debbarma · Pharmaceutical Business review_ With this validation, the agency will begin its formal assessment of the application. The submission is supported by efficacy and safety data from the Phase III VALOR clinical The post EMA validates Pfizer and Valneva’s Lyme disease vaccine appeared first on Pharmaceutical Business review . ## [FDA grants fast track status to Phanes’ spevatamig for advanced BTC](https://pharmaceutical-business-review.com/news/fda-fast-track-phanes-spevatamig/) _2026-08-17 · Salong Debbarma · Pharmaceutical Business review_ The company is evaluating spevatamig in Phase II clinical studies for various gastrointestinal cancers. Spevatamig is a bispecific antibody targeting claudin 18.2 and cluster of differentiation 47 (CD47), The post FDA grants fast track status to Phanes’ spevatamig for advanced BTC appeared first on Pharmaceutical Business review . ## [100,000 Bonus Points Await You (Sponsored)](https://crawlproof.com/a/XNKxys27PUSv) _2026-08-17 · **Sponsored**_ Earn 100,000 bonus points after spending $5,000 in the first 3 months. ## [BMS secures FDA accelerated approval for Zenbexus in multiple myeloma](https://pharmaceutical-business-review.com/news/bms-fda-zenbexus-in-multiple-myeloma/) _2026-08-14 · Salong Debbarma · Pharmaceutical Business review_ The combination is intended for patients who have previously received at least one line of therapy that included both a proteasome inhibitor and an immunomodulatory agent. Zenbexus is The post BMS secures FDA accelerated approval for Zenbexus in multiple myeloma appeared first on Pharmaceutical Business review . ## [Xanadu and University of Alberta to develop quantum algorithms for cancer](https://pharmaceutical-business-review.com/news/xanadu-university-of-alberta-quantum-algorithms-cancer/) _2026-08-14 · Salong Debbarma · Pharmaceutical Business review_ The collaboration aims to develop new quantum algorithms that could accelerate the design of next-generation photosensitisers for photodynamic therapy, a non-invasive treatment approach targeting tumour cells. The project The post Xanadu and University of Alberta to develop quantum algorithms for cancer appeared first on Pharmaceutical Business review .